Literature DB >> 15296890

Limitations of additive EuroSCORE for measuring risk stratified mortality in combined coronary and valve surgery.

Shishir Karthik1, Arun K Srinivasan, Antony D Grayson, Mark Jackson, David A C Sharpe, Daniel J M Keenan, Ben Bridgewater, Brian M Fabri.   

Abstract

OBJECTIVE: To study the use of the additive and logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) to predict mortality following adult combined coronary artery bypass grafting (CABG) and valve surgery.
METHODS: Data were collected prospectively, from all four centres providing adult cardiac surgery in the north west of England, on 1769 consecutive patients undergoing combined CABG and valve surgery between April 1997 and March 2002. Observed in-hospital mortality was compared to predicted mortality as determined by both additive and logistic EuroSCORE.
RESULTS: Observed mortality for simultaneous CABG and valve surgery was 8.7%, compared to 6.7% (additive) and 9.4% (logistic). Sixty-five percent of patients were classified as high-risk (additive EuroSCORE >5); the observed mortality was 11.5%, compared to 8.1% (additive) and 12.8% (logistic). Discrimination was similar in both systems as measured by the C statistic (additive 0.73, logistic 0.73).
CONCLUSIONS: The logistic EuroSCORE is more accurate at predicting mortality in simultaneous CABG and valve surgery, as the additive EuroSCORE significantly under-predicts in this high-risk group.

Entities:  

Mesh:

Year:  2004        PMID: 15296890     DOI: 10.1016/j.ejcts.2004.02.007

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  9 in total

1.  Performance of EuroSCORE II compared to EuroSCORE I in predicting operative and mid-term mortality of patients from a single center after combined coronary artery bypass grafting and aortic valve replacement.

Authors:  Kyriakos Spiliopoulos; Vasilis Bagiatis; Oliver Deutsch; Bernhard M Kemkes; Nikolaos Antonopoulos; Dimos Karangelis; Ayman Haschemi; Brigitte Gansera
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-08-29

2.  A novel clinical prediction rule for 30-day mortality following balloon aortic valuloplasty: the CRRAC the AV score.

Authors:  Sammy Elmariah; Steven A Lubitz; Amil M Shah; Marc A Miller; Dheeraj Kaplish; Sharad Kothari; Pedro R Moreno; Annapoorna S Kini; Samin K Sharma
Journal:  Catheter Cardiovasc Interv       Date:  2011-03-16       Impact factor: 2.692

3.  Surgical management of coexisting coronary artery and valvular heart disease.

Authors:  Sak Lee; Byung-Chul Chang; Kyung-Jong Yoo
Journal:  Yonsei Med J       Date:  2010-05       Impact factor: 2.759

4.  The logistic EuroSCORE in cardiac surgery: how well does it predict operative risk?

Authors:  F Bhatti; A D Grayson; G Grotte; B M Fabri; J Au; M Jones; B Bridgewater
Journal:  Heart       Date:  2006-03-17       Impact factor: 5.994

5.  Combined cardiac surgical procedures in octogenarians: operative outcome.

Authors:  H Gulbins; A Malkoc; J Ennker
Journal:  Clin Res Cardiol       Date:  2008-01-14       Impact factor: 5.460

6.  Impact of type of procedure and surgeon on EuroSCORE operative risk validation.

Authors:  Fernando A Atik; Claudio Ribeiro da Cunha
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Apr-Jun

7.  Discriminative Power of EuroSCORE in Predicting Morbidity and Prolonged Hospital Stay in an Iranian Sample Population.

Authors:  Mahdi Najafi; Mehrdad Sheikhvatan; Mahmood Sheikhfathollahi
Journal:  J Tehran Heart Cent       Date:  2014-01-12

8.  30-day mortality versus 1 year mortality in post cardiac surgery in adults.

Authors:  Yatin Mehta
Journal:  Ann Card Anaesth       Date:  2015 Apr-Jun

9.  Comparison of the additive, logistic european system for cardiac operative risk (EuroSCORE) with the EuroSCORE 2 to predict mortality in high-risk cardiac surgery.

Authors:  Laura Guillet; Pierre H Moury; Damien Bedague; Michel Durand; Cécile Martin; Jean F Payen; Olivier Chavanon; Pierre Albaladejo
Journal:  Ann Card Anaesth       Date:  2020 Jul-Sep
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.